ºÝºÝߣ

ºÝºÝߣShare a Scribd company logo
§£§Ú§Ù§å§Ñ§Ý§Ú§Ù§Ñ§è§Ú§ñ §Õ§Ñ§ß§ß§í§ç §Ó BI-§á§â§à§Ö§Ü§ä§Ñ§ç
§¡§Ý§Ö§Ü§ã§Ñ§ß§Õ§â §¬§å§Ý§Ú§Ü§à§Ó
§²§å§Ü§à§Ó§à§Õ§Ú§ä§Ö§Ý§î §à§ä§Õ§Ö§Ý§Ñ BI / Bayer Healthcare
§Þ§Ö§Ø§Õ§å§ß§Ñ§â§à§Õ§ß§í§Û §Ü§à§ß§è§Ö§â§ß §ã§à §ã§á§Ö§è§Ú§Ñ§Ý§Ú§Ù§Ñ§è§Ú§Ö§Û
§Ó §à§Ò§Ý§Ñ§ã§ä§Ú §Ù§Õ§â§Ñ§Ó§à§à§ç§â§Ñ§ß§Ö§ß§Ú§ñ, §ã§Ö§Ý§î§ã§Ü§à§Ô§à
§ç§à§Ù§ñ§Û§ã§ä§Ó§Ñ §Ú §Ó§í§ã§à§Ü§à§ä§Ö§ç§ß§à§Ý§à§Ô§Ú§é§ß§í§ç
§Þ§Ñ§ä§Ö§â§Ú§Ñ§Ý§à§Ó
Bayer
2 / 21
Bayer Healthcare
§±§à§Õ§â§Ñ§Ù§Õ§Ö§Ý§Ö§ß§Ú§ñ
Consumer Care Medical Care Animal HealthPharmaceuticals
? §­§Ö§Ü§Ñ§â§ã§ä§Ó§Ñ §Õ§Ý§ñ
§Ø§Ú§Ó§à§ä§ß§í§ç
? §³§à§á§å§ä§ã§ä§Ó§å§ð§ë§Ú§Ö
§ä§à§Ó§Ñ§â§í §Õ§Ý§ñ §Ø§Ú§Ó§à§ä§ß§í§ç
? §­§Ö§é§Ö§ß§Ú§Ö §Õ§Ú§Ñ§Ò§Ö§ä§Ñ:
§ã§Ú§ã§ä§Ö§Þ§í §Þ§à§ß§Ú§ä§à§â§Ú§ß§Ô§Ñ
§Ú §Ñ§Ü§ã§Ö§ã§ã§å§Ñ§â§í
? §²§Ñ§Õ§Ú§à§Ý§à§Ô§Ú§ñ
? §¢§Ö§Ù§â§Ö§è§Ö§á§ä§å§â§ß§í§Ö
§á§â§Ö§á§Ñ§â§Ñ§ä§í
? §£§Ú§ä§Ñ§Þ§Ú§ß§í §Ú §á§Ú§ë§Ö§Ó§í§Ö
§Õ§à§Ò§Ñ§Ó§Ü§Ú
? §¥§Ö§â§Þ§Ñ§ä§à§Ý§à§Ô§Ú§ñ Rx
? §­§Ö§Ü§Ñ§â§ã§ä§Ó§Ö§ß§ß§í§Ö
§á§â§Ö§á§Ñ§â§Ñ§ä§í §Õ§Ý§ñ §à§Ò§ë§Ö§Û
§ä§Ö§â§Ñ§á§Ú§Ú
? §³§á§Ö§è§Ú§Ñ§Ý§Ú§Ù§Ú§â§à§Ó§Ñ§ß§ß§í§Ö
§Ý§Ö§Ü§Ñ§â§ã§ä§Ó§Ö§ß§ß§í§Ö
§á§â§Ö§á§Ñ§â§Ñ§ä§í
3 / 21
? Advantage?
product line
? Baycox?
? Baytril?
? Drontal?
product line
? Seresto?
? Adalat?
? Aspirin? Cardio
? Avalox? / Avelox?
? Cipro? / Ciprobay?
? Glucobay?
? Levitra?
? Mirena?
product family
? Xarelto?
? YAZ? / Yasmin? /
Yasminelle?
? Zetia?
? Adempas?
? Betaferon? /
Betaseron?
? Eylea?
? Kogenate?
? Nexavar?
? Stivarga?
? Xofigo?
? Aleve?
? Aspirin?
? Bepanthen? /
Bepanthol?
? Canesten?
? Claritin?
? Coppertone?
? Dr. Scholl¡¯s?
? One A Day?
? Supradyn?
? Avanta?
? Contour?
? Gadovist? /
Gadavist?
? Iopamiron?
? Magnevist?
? Primovist?
? Ultravist?
? Stellant?
Animal HealthPharma Medical CareConsumer Care
§­§Ö§Ü§Ñ§â§ã§ä§Ó§Ö§ß§ß§í§Ö
§á§â§Ö§á§Ñ§â§Ñ§ä§í §Õ§Ý§ñ
§à§Ò§ë§Ö§Û §ä§Ö§â§Ñ§á§Ú§Ú
§³§á§Ö§è§Ú§Ñ§Ý§Ú§Ù§Ú§â§à§Ó§Ñ§ß
-§ß§í§Ö
§Ý§Ö§Ü§Ñ§â§ã§ä§Ó§Ö§ß§ß§í§Ö
§á§â§Ö§á§Ñ§â§Ñ§ä§í
Bayer Healthcare
§­§Ú§Õ§Ö§â§í §á§â§à§Õ§Ñ§Ø
4 / 21
BI §Ó Bayer Pharma
23 §Ú§ã§ä§à§é§ß§Ú§Ü§Ñ §Õ§Ñ§ß§ß§í§ç
§Ò§à§Ý§Ö§Ö 600 §á§à§Ý§î§Ù§à§Ó§Ñ§ä§Ö§Ý§Ö§Û
§Ò§à§Ý§Ö§Ö 130 §à§ä§é§Ö§ä§à§Ó
5 / 21
§£§Ú§Ù§å§Ñ§Ý§Ú§Ù§Ñ§è§Ú§ñ ¨C §Ó§Ñ§Ø§ß§Ö§Û§ê§Ñ§ñ §é§Ñ§ã§ä§î BI
§°§ä§é§Ö§ä§í
§©§Ñ§Ô§â§å§Ù§Ü§Ñ §Õ§Ñ§ß§ß§í§ç
§°§é§Ú§ã§ä§Ü§Ñ §Õ§Ñ§ß§ß§í§ç
§²§Ñ§Ù§â§Ñ§Ò§à§ä§Ü§Ñ §ç§â§Ñ§ß§Ú§Ý§Ú§ë§Ñ
§²§Ñ§Ù§â§Ñ§Ò§à§ä§Ü§Ñ OLAP-§Ü§å§Ò§à§Ó
§²§Ñ§Ù§â§Ñ§Ò§à§ä§Ü§Ñ §à§ä§é§Ö§ä§à§Ó
6 / 21
§±§â§Ñ§Ó§Ú§Ý§î§ß§Ñ§ñ §Ó§Ú§Ù§å§Ñ§Ý§Ú§Ù§Ñ§è§Ú§ñ ¨C §å§ã§á§Ö§ç BI-§á§â§à§Ö§Ü§ä§Ñ
§µ§Ó§Ö§Ý§Ú§é§Ú§Ó§Ñ§Ö§ä§ã§ñ §ã§Ü§à§â§à§ã§ä§î §Ó§à§ã§á§â§Ú§ñ§ä§Ú§ñ §Ú§ß§æ§à§â§Þ§Ñ§è§Ú§Ú
§³§Ü§Ý§Ñ§Õ§í§Ó§Ñ§Ö§ä§ã§ñ §ß§å§Ø§ß§à§Ö §Ó§á§Ö§é§Ñ§ä§Ý§Ö§ß§Ú§Ö, §æ§à§â§Þ§Ú§â§å§Ö§ä§ã§ñ §Ú§ã§ä§à§â§Ú§ñ
§³§à§Ù§Õ§Ñ§Ö§ä§ã§ñ §Õ§à§Ó§Ö§â§Ú§Ö §Ü §à§ä§é§Ö§ä§Ñ§Þ
7 / 21
§µ§Ó§Ö§Ý§Ú§é§Ú§Ó§Ñ§Ö§ä§ã§ñ §ã§Ü§à§â§à§ã§ä§î §Ó§à§ã§á§â§Ú§ñ§ä§Ú§ñ
§£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú
8 / 21
§³§à§Ù§Õ§Ñ§Ö§ä§ã§ñ §á§â§Ñ§Ó§Ú§Ý§î§ß§à§Ö §Ó§á§Ö§é§Ñ§ä§Ý§Ö§ß§Ú§Ö
Excel §á§à §å§Þ§à§Ý§é§Ñ§ß§Ú§ð §º§Ü§Ñ§Ý§Ñ §à§ä 0
9 / 21
§£§á§Ö§é§Ñ§ä§Ý§Ö§ß§Ú§Ö §Ù§Ñ§Ó§Ú§ã§Ú§ä §à§ä §Ó§Ú§Ù§å§Ñ§Ý§Ú§Ù§Ñ§è§Ú§Ú
Pie-chart Bar-chart
10 / 21
§¥§Ö§ä§Ñ§Ý§Ú ¨C §Ü§Ý§ð§é §Ü §Õ§à§Ó§Ö§â§Ú§ð
§º§â§Ú§æ§ä§í: §è§Ó§Ö§ä, §â§Ñ§Ù§Þ§Ö§â, §ã§ä§Ú§Ý§î
§¶§à§â§Þ§Ñ§ä §é§Ú§ã§Ö§Ý
§¯§Ñ§Ù§Ó§Ñ§ß§Ú§ñ §à§ã§Ö§Û §Ú §Ý§Ö§Ô§Ö§ß§Õ§í
§²§Ñ§ã§á§à§Ý§à§Ø§Ö§ß§Ú§Ö §ï§Ý§Ö§Þ§Ö§ß§ä§à§Ó, §Ó§í§â§Ñ§Ó§ß§Ú§Ó§Ñ§ß§Ú§ñ
§£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú
11 / 21
§¶§Ú§Ù§Ú§à§Ý§à§Ô§Ú§ñ ¨C §à§ã§ß§à§Ó§Ñ §á§à§Õ§ç§à§Õ§Ñ §Ü §Ó§Ú§Ù§å§Ñ§Ý§Ú§Ù§Ñ§è§Ú§Ú
70% §Ó§ã§Ö§Û §Ó§ç§à§Õ§ñ§ë§Ö§Û §Ú§ß§æ§à§â§Þ§Ñ§è§Ú§Ú §á§à§ã§ä§å§á§Ñ§Ö§ä §é§Ö§â§Ö§Ù §Ù§â§Ö§ß§Ú§Ö
12 / 21
§£§à§ã§á§â§Ú§ñ§ä§Ú§Ö §ß§Ñ §å§â§à§Ó§ß§Ö §Ú§ß§ã§ä§Ú§ß§Ü§ä§à§Ó
§±§à§á§â§à§Ò§å§Û§ä§Ö §ß§Ñ§Û§ä§Ú §Ó§ã§Ö §è§Ú§æ§â§í ?6?
13 / 21
§£§à§ã§á§â§Ú§ñ§ä§Ú§Ö §ß§Ñ §å§â§à§Ó§ß§Ö §Ú§ß§ã§ä§Ú§ß§Ü§ä§à§Ó
14 / 21
§µ§Ó§Ö§Ý§Ú§é§Ú§Ó§Ñ§ä§î ?data-ink ratio? (E. Tufte)
§£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú
§µ§Ó§Ö§Ý§Ú§é§Ú§Ó§Ñ§Ö§Þ §Ü§à§Ý§Ú§é§Ö§ã§ä§Ó§à
§ã§Þ§í§ã§Ý§à§Ó§í§ç §ï§Ý§Ö§Þ§Ö§ß§ä§à§Ó
§µ§Þ§Ö§ß§î§ê§Ñ§Ö§Þ §Ü§à§Ý§Ú§é§Ö§ã§ä§Ó§à
§Ó§ã§á§à§Þ§à§Ô§Ñ§ä§Ö§Ý§î§ß§í§ç §ï§Ý§Ö§Þ§Ö§ß§ä§à§Ó
15 / 21
§±§â§Ú§Þ§Ö§â§í ¨C §ï§æ§æ§Ö§Ü§ä§Ú§Ó§ß§à§ã§ä§î §ã§à§ä§â§å§Õ§ß§Ú§Ü§à§Ó
§£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú
16 / 21
§±§â§Ú§Þ§Ö§â§í ¨C §Õ§Ú§ß§Ñ§Þ§Ú§Ü§Ñ §á§â§à§Õ§Ñ§Ø
§£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú
17 / 21
§±§â§Ú§Þ§Ö§â§í ¨C §Õ§Ú§ß§Ñ§Þ§Ú§Ü§Ñ §á§â§à§Õ§Ñ§Ø
§£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú
18 / 21
§±§â§Ú§Þ§Ö§â§í ¨C §Õ§à§Ý§Ú §â§Ö§Ô§Ú§à§ß§à§Ó
§£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú
19 / 21
§±§â§Ú§ß§è§Ú§á§í §â§Ñ§Ù§â§Ñ§Ò§à§ä§Ü§Ú (§Þ§Ñ§Ü§ã§Ú§Þ§í §±. §¤§â§Ñ§Û§ã§Ñ)
§¬§à§Ý§Ú§é§Ö§ã§ä§Ó§à (§á§à§Ý§ß§à§ä§Ñ) §Ú§ß§æ§à§â§Þ§Ñ§è§Ú§Ú
§¯§Ö §Þ§Ö§ß§î§ê§Ö, §é§Ö§Þ §ß§å§Ø§ß§à
§¯§Ö §Ò§à§Ý§î§ê§Ö, §é§Ö§Þ §ß§å§Ø§ß§à
§¬§Ñ§é§Ö§ã§ä§Ó§à §Õ§Ñ§ß§ß§í§ç
§¯§Ö §á§à§Ü§Ñ§Ù§í§Ó§Ñ§ä§î §ß§Ö§Õ§à§ã§ä§à§Ó§Ö§â§ß§í§Ö §Õ§Ñ§ß§ß§í§Ö
§¯§Ö §á§à§Ü§Ñ§Ù§í§Ó§Ñ§ä§î §Õ§Ñ§ß§ß§í§Ö §Ò§Ö§Ù §Õ§à§ã§ä§Ñ§ä§à§é§ß§í§ç
§à§ã§ß§à§Ó§Ñ§ß§Ú§Û
§±§à§Õ§Ñ§é§Ñ
§ª§Ù§Ò§Ö§Ô§Ñ§ä§î §ß§Ö§á§à§ß§ñ§ä§ß§í§ç §ä§Ö§â§Þ§Ú§ß§à§Ó
§ª§Ù§Ò§Ö§Ô§Ñ§ä§î §ß§Ö§à§Õ§ß§à§Ù§ß§Ñ§é§ß§à§ã§ä§Ú
§¬§â§Ñ§ä§Ü§à§ã§ä§î
§±§à§ã§Ý§Ö§Õ§à§Ó§Ñ§ä§Ö§Ý§î§ß§à§ã§ä§î
§²§Ö§Ý§Ö§Ó§Ñ§ß§ä§ß§à§ã§ä§î
§¯§Ö §à§ä§Ü§Ý§à§ß§ñ§ä§î§ã§ñ §à§ä §ä§Ö§Þ§í
20 / 21
§³§á§Ñ§ã§Ú§Ò§à §Ù§Ñ §Ó§ß§Ú§Þ§Ñ§ß§Ú§Ö
§¡§Ý§Ö§Ü§ã§Ñ§ß§Õ§â §¬§å§Ý§Ú§Ü§à§Ó
§²§å§Ü§à§Ó§à§Õ§Ú§ä§Ö§Ý§î §à§ä§Õ§Ö§Ý§Ñ BI / Bayer Healthcare
alexander.kulikov@bayer.com
http://ru.linkedin.com/in/aleksanderkulikov

More Related Content

§£§Ú§Ù§å§Ñ§Ý§Ú§Ù§Ñ§è§Ú§ñ §Õ§Ñ§ß§ß§í§ç §Ó BI-§á§â§à§Ö§Ü§ä§Ñ§ç

  • 1. §£§Ú§Ù§å§Ñ§Ý§Ú§Ù§Ñ§è§Ú§ñ §Õ§Ñ§ß§ß§í§ç §Ó BI-§á§â§à§Ö§Ü§ä§Ñ§ç §¡§Ý§Ö§Ü§ã§Ñ§ß§Õ§â §¬§å§Ý§Ú§Ü§à§Ó §²§å§Ü§à§Ó§à§Õ§Ú§ä§Ö§Ý§î §à§ä§Õ§Ö§Ý§Ñ BI / Bayer Healthcare
  • 2. §Þ§Ö§Ø§Õ§å§ß§Ñ§â§à§Õ§ß§í§Û §Ü§à§ß§è§Ö§â§ß §ã§à §ã§á§Ö§è§Ú§Ñ§Ý§Ú§Ù§Ñ§è§Ú§Ö§Û §Ó §à§Ò§Ý§Ñ§ã§ä§Ú §Ù§Õ§â§Ñ§Ó§à§à§ç§â§Ñ§ß§Ö§ß§Ú§ñ, §ã§Ö§Ý§î§ã§Ü§à§Ô§à §ç§à§Ù§ñ§Û§ã§ä§Ó§Ñ §Ú §Ó§í§ã§à§Ü§à§ä§Ö§ç§ß§à§Ý§à§Ô§Ú§é§ß§í§ç §Þ§Ñ§ä§Ö§â§Ú§Ñ§Ý§à§Ó Bayer 2 / 21
  • 3. Bayer Healthcare §±§à§Õ§â§Ñ§Ù§Õ§Ö§Ý§Ö§ß§Ú§ñ Consumer Care Medical Care Animal HealthPharmaceuticals ? §­§Ö§Ü§Ñ§â§ã§ä§Ó§Ñ §Õ§Ý§ñ §Ø§Ú§Ó§à§ä§ß§í§ç ? §³§à§á§å§ä§ã§ä§Ó§å§ð§ë§Ú§Ö §ä§à§Ó§Ñ§â§í §Õ§Ý§ñ §Ø§Ú§Ó§à§ä§ß§í§ç ? §­§Ö§é§Ö§ß§Ú§Ö §Õ§Ú§Ñ§Ò§Ö§ä§Ñ: §ã§Ú§ã§ä§Ö§Þ§í §Þ§à§ß§Ú§ä§à§â§Ú§ß§Ô§Ñ §Ú §Ñ§Ü§ã§Ö§ã§ã§å§Ñ§â§í ? §²§Ñ§Õ§Ú§à§Ý§à§Ô§Ú§ñ ? §¢§Ö§Ù§â§Ö§è§Ö§á§ä§å§â§ß§í§Ö §á§â§Ö§á§Ñ§â§Ñ§ä§í ? §£§Ú§ä§Ñ§Þ§Ú§ß§í §Ú §á§Ú§ë§Ö§Ó§í§Ö §Õ§à§Ò§Ñ§Ó§Ü§Ú ? §¥§Ö§â§Þ§Ñ§ä§à§Ý§à§Ô§Ú§ñ Rx ? §­§Ö§Ü§Ñ§â§ã§ä§Ó§Ö§ß§ß§í§Ö §á§â§Ö§á§Ñ§â§Ñ§ä§í §Õ§Ý§ñ §à§Ò§ë§Ö§Û §ä§Ö§â§Ñ§á§Ú§Ú ? §³§á§Ö§è§Ú§Ñ§Ý§Ú§Ù§Ú§â§à§Ó§Ñ§ß§ß§í§Ö §Ý§Ö§Ü§Ñ§â§ã§ä§Ó§Ö§ß§ß§í§Ö §á§â§Ö§á§Ñ§â§Ñ§ä§í 3 / 21
  • 4. ? Advantage? product line ? Baycox? ? Baytril? ? Drontal? product line ? Seresto? ? Adalat? ? Aspirin? Cardio ? Avalox? / Avelox? ? Cipro? / Ciprobay? ? Glucobay? ? Levitra? ? Mirena? product family ? Xarelto? ? YAZ? / Yasmin? / Yasminelle? ? Zetia? ? Adempas? ? Betaferon? / Betaseron? ? Eylea? ? Kogenate? ? Nexavar? ? Stivarga? ? Xofigo? ? Aleve? ? Aspirin? ? Bepanthen? / Bepanthol? ? Canesten? ? Claritin? ? Coppertone? ? Dr. Scholl¡¯s? ? One A Day? ? Supradyn? ? Avanta? ? Contour? ? Gadovist? / Gadavist? ? Iopamiron? ? Magnevist? ? Primovist? ? Ultravist? ? Stellant? Animal HealthPharma Medical CareConsumer Care §­§Ö§Ü§Ñ§â§ã§ä§Ó§Ö§ß§ß§í§Ö §á§â§Ö§á§Ñ§â§Ñ§ä§í §Õ§Ý§ñ §à§Ò§ë§Ö§Û §ä§Ö§â§Ñ§á§Ú§Ú §³§á§Ö§è§Ú§Ñ§Ý§Ú§Ù§Ú§â§à§Ó§Ñ§ß -§ß§í§Ö §Ý§Ö§Ü§Ñ§â§ã§ä§Ó§Ö§ß§ß§í§Ö §á§â§Ö§á§Ñ§â§Ñ§ä§í Bayer Healthcare §­§Ú§Õ§Ö§â§í §á§â§à§Õ§Ñ§Ø 4 / 21
  • 5. BI §Ó Bayer Pharma 23 §Ú§ã§ä§à§é§ß§Ú§Ü§Ñ §Õ§Ñ§ß§ß§í§ç §Ò§à§Ý§Ö§Ö 600 §á§à§Ý§î§Ù§à§Ó§Ñ§ä§Ö§Ý§Ö§Û §Ò§à§Ý§Ö§Ö 130 §à§ä§é§Ö§ä§à§Ó 5 / 21
  • 6. §£§Ú§Ù§å§Ñ§Ý§Ú§Ù§Ñ§è§Ú§ñ ¨C §Ó§Ñ§Ø§ß§Ö§Û§ê§Ñ§ñ §é§Ñ§ã§ä§î BI §°§ä§é§Ö§ä§í §©§Ñ§Ô§â§å§Ù§Ü§Ñ §Õ§Ñ§ß§ß§í§ç §°§é§Ú§ã§ä§Ü§Ñ §Õ§Ñ§ß§ß§í§ç §²§Ñ§Ù§â§Ñ§Ò§à§ä§Ü§Ñ §ç§â§Ñ§ß§Ú§Ý§Ú§ë§Ñ §²§Ñ§Ù§â§Ñ§Ò§à§ä§Ü§Ñ OLAP-§Ü§å§Ò§à§Ó §²§Ñ§Ù§â§Ñ§Ò§à§ä§Ü§Ñ §à§ä§é§Ö§ä§à§Ó 6 / 21
  • 7. §±§â§Ñ§Ó§Ú§Ý§î§ß§Ñ§ñ §Ó§Ú§Ù§å§Ñ§Ý§Ú§Ù§Ñ§è§Ú§ñ ¨C §å§ã§á§Ö§ç BI-§á§â§à§Ö§Ü§ä§Ñ §µ§Ó§Ö§Ý§Ú§é§Ú§Ó§Ñ§Ö§ä§ã§ñ §ã§Ü§à§â§à§ã§ä§î §Ó§à§ã§á§â§Ú§ñ§ä§Ú§ñ §Ú§ß§æ§à§â§Þ§Ñ§è§Ú§Ú §³§Ü§Ý§Ñ§Õ§í§Ó§Ñ§Ö§ä§ã§ñ §ß§å§Ø§ß§à§Ö §Ó§á§Ö§é§Ñ§ä§Ý§Ö§ß§Ú§Ö, §æ§à§â§Þ§Ú§â§å§Ö§ä§ã§ñ §Ú§ã§ä§à§â§Ú§ñ §³§à§Ù§Õ§Ñ§Ö§ä§ã§ñ §Õ§à§Ó§Ö§â§Ú§Ö §Ü §à§ä§é§Ö§ä§Ñ§Þ 7 / 21
  • 8. §µ§Ó§Ö§Ý§Ú§é§Ú§Ó§Ñ§Ö§ä§ã§ñ §ã§Ü§à§â§à§ã§ä§î §Ó§à§ã§á§â§Ú§ñ§ä§Ú§ñ §£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú 8 / 21
  • 9. §³§à§Ù§Õ§Ñ§Ö§ä§ã§ñ §á§â§Ñ§Ó§Ú§Ý§î§ß§à§Ö §Ó§á§Ö§é§Ñ§ä§Ý§Ö§ß§Ú§Ö Excel §á§à §å§Þ§à§Ý§é§Ñ§ß§Ú§ð §º§Ü§Ñ§Ý§Ñ §à§ä 0 9 / 21
  • 10. §£§á§Ö§é§Ñ§ä§Ý§Ö§ß§Ú§Ö §Ù§Ñ§Ó§Ú§ã§Ú§ä §à§ä §Ó§Ú§Ù§å§Ñ§Ý§Ú§Ù§Ñ§è§Ú§Ú Pie-chart Bar-chart 10 / 21
  • 11. §¥§Ö§ä§Ñ§Ý§Ú ¨C §Ü§Ý§ð§é §Ü §Õ§à§Ó§Ö§â§Ú§ð §º§â§Ú§æ§ä§í: §è§Ó§Ö§ä, §â§Ñ§Ù§Þ§Ö§â, §ã§ä§Ú§Ý§î §¶§à§â§Þ§Ñ§ä §é§Ú§ã§Ö§Ý §¯§Ñ§Ù§Ó§Ñ§ß§Ú§ñ §à§ã§Ö§Û §Ú §Ý§Ö§Ô§Ö§ß§Õ§í §²§Ñ§ã§á§à§Ý§à§Ø§Ö§ß§Ú§Ö §ï§Ý§Ö§Þ§Ö§ß§ä§à§Ó, §Ó§í§â§Ñ§Ó§ß§Ú§Ó§Ñ§ß§Ú§ñ §£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú 11 / 21
  • 12. §¶§Ú§Ù§Ú§à§Ý§à§Ô§Ú§ñ ¨C §à§ã§ß§à§Ó§Ñ §á§à§Õ§ç§à§Õ§Ñ §Ü §Ó§Ú§Ù§å§Ñ§Ý§Ú§Ù§Ñ§è§Ú§Ú 70% §Ó§ã§Ö§Û §Ó§ç§à§Õ§ñ§ë§Ö§Û §Ú§ß§æ§à§â§Þ§Ñ§è§Ú§Ú §á§à§ã§ä§å§á§Ñ§Ö§ä §é§Ö§â§Ö§Ù §Ù§â§Ö§ß§Ú§Ö 12 / 21
  • 13. §£§à§ã§á§â§Ú§ñ§ä§Ú§Ö §ß§Ñ §å§â§à§Ó§ß§Ö §Ú§ß§ã§ä§Ú§ß§Ü§ä§à§Ó §±§à§á§â§à§Ò§å§Û§ä§Ö §ß§Ñ§Û§ä§Ú §Ó§ã§Ö §è§Ú§æ§â§í ?6? 13 / 21
  • 14. §£§à§ã§á§â§Ú§ñ§ä§Ú§Ö §ß§Ñ §å§â§à§Ó§ß§Ö §Ú§ß§ã§ä§Ú§ß§Ü§ä§à§Ó 14 / 21
  • 15. §µ§Ó§Ö§Ý§Ú§é§Ú§Ó§Ñ§ä§î ?data-ink ratio? (E. Tufte) §£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú §µ§Ó§Ö§Ý§Ú§é§Ú§Ó§Ñ§Ö§Þ §Ü§à§Ý§Ú§é§Ö§ã§ä§Ó§à §ã§Þ§í§ã§Ý§à§Ó§í§ç §ï§Ý§Ö§Þ§Ö§ß§ä§à§Ó §µ§Þ§Ö§ß§î§ê§Ñ§Ö§Þ §Ü§à§Ý§Ú§é§Ö§ã§ä§Ó§à §Ó§ã§á§à§Þ§à§Ô§Ñ§ä§Ö§Ý§î§ß§í§ç §ï§Ý§Ö§Þ§Ö§ß§ä§à§Ó 15 / 21
  • 16. §±§â§Ú§Þ§Ö§â§í ¨C §ï§æ§æ§Ö§Ü§ä§Ú§Ó§ß§à§ã§ä§î §ã§à§ä§â§å§Õ§ß§Ú§Ü§à§Ó §£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú 16 / 21
  • 17. §±§â§Ú§Þ§Ö§â§í ¨C §Õ§Ú§ß§Ñ§Þ§Ú§Ü§Ñ §á§â§à§Õ§Ñ§Ø §£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú 17 / 21
  • 18. §±§â§Ú§Þ§Ö§â§í ¨C §Õ§Ú§ß§Ñ§Þ§Ú§Ü§Ñ §á§â§à§Õ§Ñ§Ø §£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú 18 / 21
  • 19. §±§â§Ú§Þ§Ö§â§í ¨C §Õ§à§Ý§Ú §â§Ö§Ô§Ú§à§ß§à§Ó §£§ã§Ö §Õ§Ñ§ß§ß§í§Ö §Ó§í§Þ§í§ê§Ý§Ö§ß§ß§í§Ö §Ú §ß§Ö §Ú§Þ§Ö§ð§ä §ß§Ú§Ü§Ñ§Ü§à§Ô§à §à§ä§ß§à§ê§Ö§ß§Ú§ñ §Ü §â§Ö§Ñ§Ý§î§ß§à§ã§ä§Ú 19 / 21
  • 20. §±§â§Ú§ß§è§Ú§á§í §â§Ñ§Ù§â§Ñ§Ò§à§ä§Ü§Ú (§Þ§Ñ§Ü§ã§Ú§Þ§í §±. §¤§â§Ñ§Û§ã§Ñ) §¬§à§Ý§Ú§é§Ö§ã§ä§Ó§à (§á§à§Ý§ß§à§ä§Ñ) §Ú§ß§æ§à§â§Þ§Ñ§è§Ú§Ú §¯§Ö §Þ§Ö§ß§î§ê§Ö, §é§Ö§Þ §ß§å§Ø§ß§à §¯§Ö §Ò§à§Ý§î§ê§Ö, §é§Ö§Þ §ß§å§Ø§ß§à §¬§Ñ§é§Ö§ã§ä§Ó§à §Õ§Ñ§ß§ß§í§ç §¯§Ö §á§à§Ü§Ñ§Ù§í§Ó§Ñ§ä§î §ß§Ö§Õ§à§ã§ä§à§Ó§Ö§â§ß§í§Ö §Õ§Ñ§ß§ß§í§Ö §¯§Ö §á§à§Ü§Ñ§Ù§í§Ó§Ñ§ä§î §Õ§Ñ§ß§ß§í§Ö §Ò§Ö§Ù §Õ§à§ã§ä§Ñ§ä§à§é§ß§í§ç §à§ã§ß§à§Ó§Ñ§ß§Ú§Û §±§à§Õ§Ñ§é§Ñ §ª§Ù§Ò§Ö§Ô§Ñ§ä§î §ß§Ö§á§à§ß§ñ§ä§ß§í§ç §ä§Ö§â§Þ§Ú§ß§à§Ó §ª§Ù§Ò§Ö§Ô§Ñ§ä§î §ß§Ö§à§Õ§ß§à§Ù§ß§Ñ§é§ß§à§ã§ä§Ú §¬§â§Ñ§ä§Ü§à§ã§ä§î §±§à§ã§Ý§Ö§Õ§à§Ó§Ñ§ä§Ö§Ý§î§ß§à§ã§ä§î §²§Ö§Ý§Ö§Ó§Ñ§ß§ä§ß§à§ã§ä§î §¯§Ö §à§ä§Ü§Ý§à§ß§ñ§ä§î§ã§ñ §à§ä §ä§Ö§Þ§í 20 / 21
  • 21. §³§á§Ñ§ã§Ú§Ò§à §Ù§Ñ §Ó§ß§Ú§Þ§Ñ§ß§Ú§Ö §¡§Ý§Ö§Ü§ã§Ñ§ß§Õ§â §¬§å§Ý§Ú§Ü§à§Ó §²§å§Ü§à§Ó§à§Õ§Ú§ä§Ö§Ý§î §à§ä§Õ§Ö§Ý§Ñ BI / Bayer Healthcare alexander.kulikov@bayer.com http://ru.linkedin.com/in/aleksanderkulikov